BioVie (NASDAQ:BIVI) Raised to “Strong-Buy” at Brookline Capital Management

BioVie (NASDAQ:BIVI) was upgraded by equities research analysts at Brookline Capital Management to a “strong-buy” rating in a note issued to investors on Tuesday,Zacks.com reports.

BioVie Stock Up 5.0 %

Shares of NASDAQ BIVI opened at $1.06 on Tuesday. The business has a fifty day simple moving average of $1.64 and a 200-day simple moving average of $2.14. The company has a market cap of $19.56 million, a price-to-earnings ratio of -0.11 and a beta of 0.51. BioVie has a 12 month low of $0.99 and a 12 month high of $7.50.

BioVie (NASDAQ:BIVI) last posted its quarterly earnings data on Tuesday, February 11th. The company reported ($0.46) EPS for the quarter.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of BIVI. NewEdge Advisors LLC grew its stake in shares of BioVie by 14,000.0% in the 4th quarter. NewEdge Advisors LLC now owns 14,100 shares of the company’s stock valued at $28,000 after buying an additional 14,000 shares in the last quarter. Squarepoint Ops LLC acquired a new stake in BioVie in the fourth quarter valued at approximately $28,000. Northern Trust Corp acquired a new stake in BioVie in the fourth quarter valued at approximately $34,000. Two Sigma Investments LP bought a new stake in BioVie in the fourth quarter worth approximately $57,000. Finally, Prosperity Wealth Management Inc. acquired a new position in shares of BioVie during the 4th quarter worth $63,000. 4.59% of the stock is owned by institutional investors and hedge funds.

BioVie Company Profile

BioVie Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease.